# Guangzhou Huajin Pharmaceutical Technology Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/guangzhou-huajin-pharmaceutical-technology-co

- Industry: Biotechnology
- Headquarters: Guangzhou, China
- Website: www.huajinpharmtech.com
- Latest round: Series B (Dec 30, 2023)
- Investors on record: 5

## About

Established in 2016 and based in Guangzhou, China, Guangzhou Huajin Pharmaceutical Technology Co., Ltd. operates as a biotechnology company that focuses on the development and production of biological oncology drugs. It has recognized as "one of the national science and technology-based small and medium-sized enterprises" in August 2021, and received IND approvals from the U.S. FDA, China Taiwan TFDA and China NMPA, and initiated international multi-center Phase I/IIa clinical trials for a variety of malignant solid tumors during 2021. In December 2023, it closed a round of series B funding.

The company focuses on the research and development of biological anti-tumor innovative drugs in the bacterial vector class. Currently, it has developed SalMet-Vec, a self-developed lysogenic bacterium, which is a genetically engineered biologic product that carries and expresses methioninase through attenuated Salmonella vectors, and exerts precisely targeted anti-tumor effects in the direction of the metabolic regulation of amino acids required for tumor growth. As the Company's pioneering core product, SalMet-Vec has already obtained IND approvals and entered the clinical trial stage in China, the United States and other places.

The company will use the series B funding raised in December 2023 for the international multi-center registration clinical study of the tumor-targeting amino acid metabolic pathway-regulated oncolytic bacterium, SalMet-Vec injection, to be carried out in mainland China, Taiwan, China and the United States.

## Funding rounds

- Series B, Dec 30, 2023 — Puxin Capital, Coastal Industry Investment
- Series A, Sep 29, 2020 — China International Capital Corporation, Winzac Capital Management
- Angel, Aug 1, 2017 — Share Capital

## Investors

- Share Capital (https://capitalatlas.ai/funds/share-capital) — Angel
- China International Capital Corporation (https://capitalatlas.ai/funds/china-international-capital-corporation) — Series A
- Winzac Capital Management (https://capitalatlas.ai/funds/winzac-capital-management) — Series A
- Puxin Capital (https://capitalatlas.ai/funds/puxin-capital) — Series B
- Coastal Industry Investment (https://capitalatlas.ai/funds/coastal-industry-investment) — Series B